Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34319
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18074/20272 (89%)
Visitors : 2436231      Online Users : 1104
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34319


    Title: Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
    Authors: Kang, Nai-Wen
    Tan, Kien-Thiam
    Li, Chien-Feng
    Kuo, Yu-Hsuan
    Contributors: Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol
    ACT Genom Co Ltd
    Chi Mei Med Ctr, Dept Med Res
    Natl Inst Canc Res, Natl Hlth Res Inst
    Chia Nan Univ, Coll Pharm & Sci
    Keywords: neuroendocrine carcinoma
    immunotherapy
    immune checkpoint inhibitor
    tumor mutational burden
    Date: 2021
    Issue Date: 2023-11-11 11:43:05 (UTC+8)
    Publisher: MDPI
    Abstract: Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment.
    Relation: CURR ONCOL, v.28, n.6, pp.4587-4596
    Appears in Collections:[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    curroncol28060388.pdf3991KbAdobe PDF70View/Open
    index.html0KbHTML213View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback